Form 4: Director Dolan Sondhi Acquires Passage BIO Stock Options

Director Dolan Sondhi acquired stock options for 10,539 shares of Passage BIO, Inc. (PASG) with an exercise price of $5.08, vesting under specific service conditions.

Summary

• Dolan Sondhi, a Director at Passage BIO, Inc., acquired a stock option grant on May 19, 2026.
• The option is for 10,539 shares of common stock.
• The exercise price for these options is $5.08 per share.
• These options are subject to vesting conditions, including continuous service to the issuer.
• The options will fully vest on the earlier of the one-year anniversary of the grant date or the date of the issuer's 2027 Annual Meeting of Stockholders, provided continuous service is maintained.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to a director, which is typical compensation and not indicative of immediate positive or negative company performance.

Positives

• Director Dolan Sondhi's acquisition of stock options indicates a continued commitment and potential for future value appreciation in Passage BIO, Inc.
• The stock option grant aligns the reporting person's interests with those of other shareholders through potential future equity ownership.

Risks

• The vesting of the stock options is contingent upon the reporting person's continuous service to the issuer, meaning any departure before the vesting date would result in forfeiture of the options.
• The value of the stock options is subject to market fluctuations and the future performance of Passage BIO, Inc.'s stock price.

Future Outlook

The stock options are exercisable and will vest based on continuous service, with full vesting occurring on the earlier of the one-year anniversary of the grant date or the issuer's 2027 Annual Meeting of Stockholders.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology sector to incentivize long-term commitment and align executive interests with shareholder value, especially for companies in development stages.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns their interests with shareholders, potentially leading to decisions that enhance long-term stock value. However, it also represents potential future dilution if options are exercised.

Next Steps

• Reporting person to maintain continuous service to Passage BIO, Inc. for options to vest.
• Options will become fully vested on the earlier of the one-year anniversary of the grant date or the issuer's 2027 Annual Meeting of Stockholders.
• Reporting person may exercise vested options until the expiration date of 05/19/2036.

Key Dates

Keywords

Form 4, SEC Filing, Stock Options, Beneficial Ownership, Passage BIO, PASG, Director, Equity Award, Vesting Schedule